Morgan Stanley’s KaloBios Pharmaceuticals KBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
– Sell
-47,139
Closed -$472K – 7065
2015
Q4
$472K Buy
+47,139
New +$522K ﹤0.01% 4588
2015
Q1
– Sell
-9,724
Closed -$135K – 6983
2014
Q4
$135K Buy
+9,724
New +$139K ﹤0.01% 5419
2014
Q3
– Sell
-288
Closed -$5K – 6946
2014
Q2
$5K Buy
288
+279
+3,100% +$4.78K ﹤0.01% 6307
2014
Q1
$0 Sell
9
-508
-98% -$14.7K ﹤0.01% 6802
2013
Q4
$19K Sell
517
-6,427
-93% -$215K ﹤0.01% 5889
2013
Q3
$251K Buy
6,944
+264
+4% +$12K ﹤0.01% 4749
2013
Q2
$303K Buy
+6,680
New +$303K ﹤0.01% 4598

Other funds holding KBIO

Morgan Stanley's KBIO Position: Q1 2016 in Review

Morgan Stanley sold out of KaloBios Pharmaceuticals (KBIO) in Q1 2016, closing a stake of 47,139 shares — an estimated $472K sold.

Morgan Stanley first reported a position in KBIO in Q2 2013 and held it in 7 quarters. The position peaked at $472K in Q4 2015. 1 fund tracked by Wall St. Rank holds KBIO as of Q1 2016.

  • Morgan Stanley reported no remaining KaloBios Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Morgan Stanley sold 47,139 KaloBios Pharmaceuticals shares in Q1 2016, an estimated $472K.
  • Morgan Stanley first reported a position in KaloBios Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Morgan Stanley's KaloBios Pharmaceuticals position peaked at $472K in Q4 2015.
  • 1 fund tracked by Wall St. Rank held KaloBios Pharmaceuticals as of Q1 2016.

Based on Morgan Stanley's 13F filing for Q1 2016, filed 12 May 2016.